News and Press Releases
Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project
Small Molecules Identified for Therapeutic Intervention in Oncology and Inflammation Edinburgh, Scotland, and Villigen, Switzerland, 20 August 2024 – Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in...
Category: Drug Discovery
Posted: August 22, 2024
Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes
Investment in state-of-the-art imaging suite to accelerate data generation with physiologically-relevant in vitro models for deeper insights on drug effects in vivo Launch of advanced lung FMT assay provides extensive...
Category: Drug Discovery
Posted: August 8, 2024
Newcells Biotech, The Biophere, Drayman's Way, newcastle Helix, Newcastle-upon-Tyne, NE4 5BX
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib1,2,3,4 ...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 26, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Deuterium Depletion Is the Key to Getting a Breakthrough in Cancer Therapy
Two review papers consolidate 30 years of research BUDAPEST, Hungary, July 25, 2024 / Biotech Newswire / -- HYD LLC for Cancer Research and Drug Development (HYD or the Company)...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 25, 2024
ViroCell Biologics signs Master Services Agreement with prominent NCI-designated cancer centre
MSA enables collaboration on full suite of ViroCell’s viral vector manufacturing services to accelerate the cancer centre’s clinical development of novel gene-modified cell therapies Agreement follows ViroCell’s successful GMP manufacture...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: July 22, 2024
Pan Cancer T secures €4.25m in Seed Extension Round to advance next-generation T cell therapies
July 11 2024, Rotterdam, the Netherlands – Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25m Seed...
Category: Drug Delivery
Posted: July 11, 2024
Concr launches trial using digital twins for outcome prediction in breast cancer
10 July 2024, London United Kingdom – Concr announces that first patients have been recruited to the VISION trial, an observational clinical study evaluating Concr’s therapeutic response predictive algorithm defining...
Category: Biotechnology
Posted: July 10, 2024
Epsilogen announces CTA approval for phase 1b trial of MOv18 IgE in platinum-resistant ovarian cancer
Phase 1b study expected to initiate in H2 2024 Previously reported phase 1 results showed MOv18 IgE to be safe and well-tolerated, with evidence of anti-tumour activity. 8 July 2024...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 8, 2024
Stockholm 3 commercially available in the US
A3P Biomedical AB, a leading Swedish diagnostics company specializing in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, are excited to announce that Stockholm3 for early detection...
Category: Biotechnology
Posted: July 3, 2024
RYBREVANT (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
Approval is supported by the phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60% compared to chemotherapy alone 28...
Category: Clinical Trials, Pharmaceutical
Posted: June 28, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
CHMP adopts positive opinion for BALVERSA (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers The CHMP’s recommendation is based on results...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 28, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Prevention and early detection of gastrointestinal cancers take on new importance amidst a younger population
Emerging research on early-onset gastrointestinal cancers highlights need for better prevention, diagnosis and treatment Less invasive, smart technologies could improve participation in and efficacy of GI cancer screening Studies presented...
Category: Other
Posted: June 27, 2024
CatSci Announces Strategic Acquisition of Reach Separations to Offer End-To-End Separation Science Support from Discovery to Manufacture
25 June 2024 - Cardiff, UK - CatSci Ltd, an award-winning innovation partner for medicines development, announces the acquisition of Reach Separations, a specialist chromatography provider for the analysis and purification...
Category: BioManufacturing, Pharmaceutical
Posted: June 25, 2024
Bio-Rad Extends Range of Anti-Biotherapeutic Antibodies to Accelerate Antibody Drug Development
Four New Anti-Idiotypic Antibodies and a New Anti-MMAE Antibody Range Support Bioanalytical Assay Development for Preclinical Research and Clinical Trials June 24 2024, California, US, -Bio-Rad Laboratories, Inc. (NYSE: BIO...
Category: BioManufacturing, Clinical Trials, Drug Discovery
Posted: June 24, 2024
Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET
New Phesi proof of concept demonstrates potential of AI-powered digital twins to replace external control arms in clinical trials
Study published in Bone Marrow Transplantation uses real-world clinical data to create virtual digital twin cohorts instead of placebo and standard-of-care comparator arms 20 June 2024 -- Massachusetts, US --...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: June 20, 2024
